CNSYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CERENOME, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.05 (-2.94%)
Close on Oct 19, 2026
- Market cap
- $11.38M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.85 (−89.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
CERENOME, INC. saw revenue fall 21.0% to $4.20M over the twelve months to Jun 30, 2026. Free cash flow was -$23.55M.
Revenue
$4.20M
-21.0% vs. a year earlier
Operating income
-$26.40M
TTM Q2 2026
Free cash flow
-$23.55M
TTM Q2 2026
EPS, diluted
-$7.25
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.38M
- P/E ratio
- –
- Price to sales
- 2.71
- Price to book
- 2.08
- Dividend yield
- –
- Free cash flow yield
- -206.88%
Fundamentals
- Revenue
- $4.20M
- Net income
- -$26.09M
- EPS, diluted
- -$7.25
- Free cash flow
- -$23.55M
- Book value per share
- $0.79
- Diluted shares
- 7M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$4.20M-21.0% YoY
Gross profit
–
Operating income
-$26.40M
Net income
-$26.09M
EPS, diluted
–
Free cash flow
-$23.55M
Reported periodTrailing twelve months